Peptonic Medical AB announces outcome of the rights issue

Peptonic Medical completed a rights issue that was 52.5% subscribed (48,577,918 units with rights and 472,387 without), raising approximately SEK 10.0m before issue costs; guarantee commitments of 13,568,880 units (≈14.5%) will be utilised. A directed set-off issue of 50,246,819 units (subscription price SEK 0.16 per unit / SEK 0.0016 per share) was also resolved; together the transactions increase shares by 11,286,600,400 to 20,624,009,514 (≈54.7% immediate dilution), and full exercise of all TO6 warrants could further raise ~SEK 18.1m and expand shares to 31,910,609,914 (additional ≈35.4% dilution).

Analysis

Market structure: Creditors and guarantors are the primary winners — they convert claims into equity and warrants, receiving ~50.2m units and a SEK ~10m immediate liquidity bridge; existing public shareholders are the clear losers with immediate dilution of ~54.7% (to 20.62bn shares) and potential total dilution to ~31.91bn shares if warrants are exercised. The massive issuance is a supply shock that will depress free‑float liquidity and likely compress the share price; product market positioning in women’s self‑care is unchanged so commercial pricing power is neutral in the near term.

Risk assessment: Tail risks include reconstruction failure (rehabilitation fails → insolvency), legal challenges to the directed set‑off, or failure to list/clear TO6 warrants — any of which could wipe equity value. Key time windows: immediate (days) for BTU conversion and week‑7 Bolagsverket registration; medium (May 18–29 VWAP) and early June (June 1–12 warrant exercise) for additional dilution/cash inflow; long term (12–24 months) for U.S./EU commercial execution to restore value.

Trade implications: Near‑term directionally bearish — anticipate selling pressure around registration and VWAP period; equity vol and derivative supply will rise. Practical trades: short the Spotlight‑listed Peptonic (via CFD or borrow) into BTU conversion and June exercise; consider small, conditional long exposure to TO6 warrants only if they trade materially below modeled intrinsic value given the exercise mechanics.

Contrarian angles: Consensus overlooks that full warrant exercise could inject up to ~SEK 18.1m (total) extending runway and reducing immediate insolvency risk, creating a capped-recovery call on distressed paper. Historical parallels show recapitalized micro‑cap biotechs can recover if they hit 12–18 month commercial milestones, so a tightly sized asymmetric play (deep short with tiny optional long exposure) is warranted rather than a blanket abandonment of the equity.

Key Decisions for Investors

• Establish a short position in Peptonic Medical (Spotlight‑listed) via CFD or locate borrow sized 1.0–1.5% of portfolio NAV targeting a 40% downside within 3 months; set stop‑loss at +25% above entry and reduce if Bolagsverket registration is delayed >2 weeks (increase to 2% NAV).
• If TO6 warrants begin trading, initiate a long warrants position up to 0.5% NAV only if market price implies ≥2x upside to the expected exercise value (i.e., warrant price <0.5× implied post‑70% VWAP intrinsic); exit into VWAP period (before May 18) or by May 31 to capture repricing into exercise window.
• Implement a pair trade: Go long consumer‑health staples (e.g., PG 2.0% NAV, UL 1.5% NAV) and short Peptonic 1.0% NAV to rotate out of small‑cap medtech risk into defensive, cash‑generative names; rebalance after June 15 depending on warrant exercise ratio.
• Reduce aggregate exposure to Nordic small‑cap medtechs by ~50% and hold proceeds in cash/stable names until post‑warrant outcome; actively monitor three catalysts — Bolagsverket registration (expected week 7), VWAP period (May 18–29), and warrant exercise window (June 1–12) — and escalate trading actions if fewer than 30% of warrants are exercised by June 15.